0105 Aro
BioCentury & Getty Images

Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

J&J spinout readying first two Centyrin-oligo conjugates for the clinic

Led by CEO Susan Dillon, the J&J spinout prepares to advance its first two Centyrin-oligo conjugates to the clinic and grow its team.

Jan 6, 2021 | 1:30 AM GMT

Read the full 584 word article

How to gain access

Continue reading with a
two-week free trial.